{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:33:34Z","timestamp":1791920014261,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["#2017-00915"],"award-info":[{"award-number":["#2017-00915"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["#2018-02532"],"award-info":[{"award-number":["#2018-02532"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["#RDAPB-201809-2016615"],"award-info":[{"award-number":["#RDAPB-201809-2016615"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["#201809-2016862"],"award-info":[{"award-number":["#201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Alzheimer Foundation","award":["#AF-930351, #AF-939721 and #AF-968270"],"award-info":[{"award-number":["#AF-930351, #AF-939721 and #AF-968270"]}]},{"name":"Hj\u00e4rnfonden, Sweden","award":["#FO2017-0243 and #ALZ2022-0006"],"award-info":[{"award-number":["#FO2017-0243 and #ALZ2022-0006"]}]},{"name":"ALF-agreement","award":["#ALFGBG-715986 and #ALFGBG-965240"],"award-info":[{"award-number":["#ALFGBG-715986 and #ALFGBG-965240"]}]},{"name":"European Union Joint Program for Neurodegenerative Disorders","award":["JPND2019-466-236"],"award-info":[{"award-number":["JPND2019-466-236"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["#1R01AG068398-01"],"award-info":[{"award-number":["#1R01AG068398-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alzheimer\u2019s Association 2021 Zenith Award","award":["ZEN-21-848495"],"award-info":[{"award-number":["ZEN-21-848495"]}]},{"name":"European Union\u2019s Horizon Europe research and innovation programme","award":["101053962"],"award-info":[{"award-number":["101053962"]}]},{"name":"Swedish State Support for Clinical Research","award":["#ALFGBG-71320"],"award-info":[{"award-number":["#ALFGBG-71320"]}]},{"name":"AD Strategic Fund and the Alzheimer's Association","award":["#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C"],"award-info":[{"award-number":["#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C"]}]},{"name":"Bluefield Project"},{"DOI":"10.13039\/501100021720","name":"Olav Thon Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007436","name":"Erling-Persson Family Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["#FO2022-0270"],"award-info":[{"award-number":["#FO2022-0270"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marie Sk\u0142odowska-Curie grant","award":["860197"],"award-info":[{"award-number":["860197"]}]},{"name":"European Union Joint Programme \u2013 Neurodegenerative Disease Research","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-980746"],"award-info":[{"award-number":["AF-980746"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen Gamla tj\u00e4narinnor","doi-asserted-by":"crossref","award":["2022-01324"],"award-info":[{"award-number":["2022-01324"]}],"id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Idiopathic Normal pressure hydrocephalus (iNPH) is a form of adult hydrocephalus that is clinically characterized by progressive gait impairment, cognitive dysfunction, and urinary incontinence. The current standard method of treatment involves surgical installation of a CSF diversion shunt. However, only a fraction of patients shows an alleviation of symptoms from shunt surgery. Thus, the purpose of this prospective explorative proteomic study was to identify prognostic CSF biomarkers to predict shunt responsiveness in iNPH patients. Further, we evaluated the ability of the core Alzheimer\u2019s disease (AD) CSF biomarkers phosphorylated (p)-tau, total (t)-tau, and amyloid-\u03b2 1\u201342 (A\u03b2<jats:sub>1\u201342<\/jats:sub>) to serve as predictors of shunt response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a tandem mass tag (TMT) proteomic analysis of lumbar CSF from 68 iNPH patients, sampled pre-shunt surgery. Tryptic digests of CSF samples were labelled with TMTpro reagents. The TMT multiplex samples were fractionated in 24 concatenated fractions by reversed-phase chromatography at basic pH and analysed by liquid chromatography coupled to mass spectrometry (LC\u2013MS) on an Orbitrap Lumos mass spectrometer. The relative abundances of the identified proteins were correlated with (i) iNPH grading scale (iNPHGS) and (ii) gait speed change 1\u00a0year after surgery from baseline to identify predictors of shunt responsiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified four CSF biomarker candidates which correlated most strongly with clinical improvement on the iNPHGS and were significantly changed in shunt-responsive compared to shunt-unresponsive iNPH patients 1\u00a0year post-surgery: FABP3 (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.46, log<jats:sub>2<\/jats:sub>(fold change (FC))\u2009=\u2009\u2212\u00a00.25, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), ANXA4 (<jats:italic>R<\/jats:italic>\u2009=\u20090.46, log<jats:sub>2<\/jats:sub>(FC)\u2009=\u20090.32, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), MIF (<jats:italic>R<\/jats:italic>\u2009=\u2009-0.49, log<jats:sub>2<\/jats:sub>(FC)\u2009=\u2009 \u2212\u00a00.20, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and B3GAT2 (<jats:italic>R<\/jats:italic>\u2009=\u20090.54, log<jats:sub>2<\/jats:sub>(FC)\u2009=\u20090.20, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In addition, five biomarker candidates were selected based on their strong correlation with gait speed change 1\u00a0year after shunt installation: ITGB1 (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.48, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), YWHAG (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.41, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), OLFM2 (<jats:italic>R<\/jats:italic>\u2009=\u20090.39, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), TGFBI (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.38, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), and DSG2 (<jats:italic>R<\/jats:italic>\u2009=\u20090.37, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n                <jats:p>Concentrations of the CSF AD core biomarkers did not differ significantly with shunt responsiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>FABP3, MIF, ANXA4, B3GAT2, ITGB1, YWHAG, OLFM2, TGFBI and DSG2 in CSF are promising prognostic biomarker candidates to predict shunt responsiveness in iNPH patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12987-023-00440-5","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:03:00Z","timestamp":1685973780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus"],"prefix":"10.1186","volume":"20","author":[{"given":"Sophia","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Junkkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Luikku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas","family":"Rauramaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarja","family":"Kokkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna-Kaisa","family":"Herukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"6","key":"440_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3171\/2019.2.JNS183538","volume":"132","author":"MA Williams","year":"2019","unstructured":"Williams MA, Nagel SJ, Luciano MG, Relkin N, Zwimpfer TJ, Katzen H, et al. The clinical spectrum of hydrocephalus in adults: report of the first 517 patients of the adult hydrocephalus clinical research network registry. J Neurosurg. 2019;132(6):1773\u201384.","journal-title":"J Neurosurg"},{"key":"440_CR2","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000168185.29659.C5","author":"N Relkin","year":"2005","unstructured":"Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005. https:\/\/doi.org\/10.1227\/01.NEU.0000168185.29659.C5.","journal-title":"Neurosurgery"},{"issue":"2","key":"440_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2176\/nmc.st.2020-0292","volume":"61","author":"M Nakajima","year":"2021","unstructured":"Nakajima M, Yamada S, Miyajima M, Ishii K, Kuriyama N, Kazui H, et al. Guidelines for management of idiopathic normal pressure hydrocephalus (third edition): endorsed by the Japanese society of normal pressure hydrocephalus. Neurol Med Chir. 2021;61(2):63\u201397.","journal-title":"Neurol Med Chir"},{"key":"440_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014923\/full","author":"A Gontsarova","year":"2022","unstructured":"Gontsarova A, Richardson D, Methley AM, Tsang K, Pearce R, Carswell C. Shunting for idiopathic normal pressure hydrocephalus. Cochrane Database Syst Rev. 2022. https:\/\/doi.org\/10.1002\/14651858.CD014923\/full.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"440_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S1474-4422(15)00046-0","volume":"14","author":"H Kazui","year":"2015","unstructured":"Kazui H, Miyajima M, Mori E, Ishikawa M. Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2): an open-label randomised trial. Lancet Neurol. 2015;14(6):585\u201394.","journal-title":"Lancet Neurol"},{"issue":"4","key":"440_CR6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/ene.14671","volume":"28","author":"K Andr\u00e9n","year":"2021","unstructured":"Andr\u00e9n K, Wikkels\u00f8 C, Hellstr\u00f6m P, Tullberg M, Jaraj D. Early shunt surgery improves survival in idiopathic normal pressure hydrocephalus. Eur J Neurol. 2021;28(4):1153\u20139.","journal-title":"Eur J Neurol"},{"issue":"10","key":"440_CR7","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00701-013-1835-5","volume":"155","author":"AK Toma","year":"2013","unstructured":"Toma AK, Papadopoulos MC, Stapleton S, Kitchen ND, Watkins LD. Systematic review of the outcome of shunt surgery in idiopathic normal-pressure hydrocephalus. Acta Neurochir. 2013;155(10):1977\u201380.","journal-title":"Acta Neurochir"},{"issue":"4","key":"440_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.25046","volume":"82","author":"AJ Espay","year":"2017","unstructured":"Espay AJ, Da Prat GA, Dwivedi AK, Rodriguez-Porcel F, Vaughan JE, Rosso M, et al. Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration. Ann Neurol. 2017;82(4):503\u201313.","journal-title":"Ann Neurol"},{"issue":"1","key":"440_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12987-019-0142-9","volume":"16","author":"A Junkkari","year":"2019","unstructured":"Junkkari A, Luikku AJ, Danner N, Jyrkk\u00e4nen HK, Rauramaa T, Korhonen VE, et al. The Kuopio idiopathic normal pressure hydrocephalus protocol: initial outcome of 175 patients. Fluids Barriers CNS. 2019;16(1):21.","journal-title":"Fluids Barriers CNS"},{"key":"440_CR10","first-page":"1","volume":"11","author":"MA Williams","year":"2022","unstructured":"Williams MA, Nagel SJ, Golomb J, Jensen H, Dasher NA, Holubkov R, et al. Safety and effectiveness of the assessment and treatment of idiopathic normal pressure hydrocephalus in the adult hydrocephalus clinical research network. J Neurosurg. 2022;11:1\u201313.","journal-title":"J Neurosurg"},{"issue":"4","key":"440_CR11","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2020.7.FOCUS20466","volume":"49","author":"H Israelsson","year":"2020","unstructured":"Israelsson H, Larsson J, Eklund A, Malm J. Risk factors, comorbidities, quality of life, and complications after surgery in idiopathic normal pressure hydrocephalus: review of the INPH-CRasH study. Neurosurg Focus. 2020;49(4):E8.","journal-title":"Neurosurg Focus"},{"issue":"387","key":"440_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2018.01.017","volume":"15","author":"YJ Hong","year":"2018","unstructured":"Hong YJ, Kim MJ, Jeong E, Kim JE, Hwang J, Lee JI, et al. Preoperative biomarkers in patients with idiopathic normal pressure hydrocephalus showing a favorable shunt surgery outcome. J Neurol Sci. 2018;15(387):21\u20136.","journal-title":"J Neurol Sci"},{"issue":"7","key":"440_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00701-022-05154-5","volume":"164","author":"SG Thavarajasingam","year":"2022","unstructured":"Thavarajasingam SG, El-Khatib M, Vemulapalli KV, Iradukunda HAS, Laleye J, Russo S, et al. Cerebrospinal fluid and venous biomarkers of shunt-responsive idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis. Acta Neurochir. 2022;164(7):1719\u201346.","journal-title":"Acta Neurochir"},{"issue":"1","key":"440_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/cjn.2017.251","volume":"45","author":"T Pfanner","year":"2018","unstructured":"Pfanner T, Henri-Bhargava A, Borchert S. Cerebrospinal fluid biomarkers as predictors of shunt response in idiopathic normal pressure hydrocephalus: a systematic review. Can J Neurol Sci. 2018;45(1):3\u201310.","journal-title":"Can J Neurol Sci"},{"issue":"10","key":"440_CR15","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00018-019-03040-5","volume":"76","author":"K Dhiman","year":"2019","unstructured":"Dhiman K, Blennow K, Zetterberg H, Martins RN, Gupta VB. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer\u2019s disease pathogenesis. Cell Mol Life Sci. 2019;76(10):1833\u201363.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"440_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jalz.2010.12.008","volume":"7","author":"D Cabral","year":"2011","unstructured":"Cabral D, Beach TG, Vedders L, Sue LI, Jacobson S, Myers K, et al. Frequency of Alzheimer\u2019s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus. Alzheimers Dement. 2011;7(5):509\u201313.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"440_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/01616412.2020.1831300","volume":"43","author":"K Migliorati","year":"2021","unstructured":"Migliorati K, Panciani PP, Pertichetti M, Borroni B, Archetti S, Rozzini L, et al. P-Tau as prognostic marker in long term follow up for patients with shunted iNPH. Neurol Res. 2021;43(1):78\u201385.","journal-title":"Neurol Res"},{"issue":"12","key":"440_CR18","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00701-017-3314-x","volume":"159","author":"CL Craven","year":"2017","unstructured":"Craven CL, Baudracco I, Zetterberg H, Lunn MPT, Chapman MD, Lakdawala N, et al. The predictive value of T-tau and AB1-42 levels in idiopathic normal pressure hydrocephalus. Acta Neurochir. 2017;159(12):2293\u2013300.","journal-title":"Acta Neurochir"},{"issue":"9","key":"440_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-8118-9-7","volume":"23","author":"S Patel","year":"2012","unstructured":"Patel S, Lee EB, Xie SX, Law A, Jackson EM, Arnold SE, et al. Phosphorylated tau\/amyloid beta 1\u201342 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS. 2012;23(9):7.","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"440_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3171\/2017.7.JNS171005","volume":"130","author":"S Abu Hamdeh","year":"2018","unstructured":"Abu Hamdeh S, Virhammar J, Sehlin D, Alafuzoff I, Cesarini KG, Marklund N. Brain tissue A\u03b242 levels are linked to shunt response in idiopathic normal pressure hydrocephalus. J Neurosurg. 2018;130(1):121\u20139.","journal-title":"J Neurosurg"},{"issue":"5","key":"440_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1600-0404.2007.00890.x","volume":"116","author":"A Agren-Wilsson","year":"2007","unstructured":"Agren-Wilsson A, Lekman A, Sj\u00f6berg W, Rosengren L, Blennow K, Bergenheim AT, et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand. 2007;116(5):333\u20139.","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"440_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1743-8454-5-9","volume":"25","author":"M Tullberg","year":"2008","unstructured":"Tullberg M, Blennow K, M\u00e5nsson JE, Fredman P, Tisell M, Wikkels\u00f6 C. Cerebrospinal fluid markers before and after shunting in patients with secondary and idiopathic normal pressure hydrocephalus. Cerebrospinal Fluid Res. 2008;25(5):9.","journal-title":"Cerebrospinal Fluid Res"},{"issue":"5","key":"440_CR23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/jcm10051105","volume":"10","author":"A Vanninen","year":"2021","unstructured":"Vanninen A, Nakajima M, Miyajima M, Rauramaa T, Kokki M, Musialowicz T, et al. Elevated CSF LRG and decreased Alzheimer\u2019s disease biomarkers in idiopathic normal pressure hydrocephalus. J Clin Med. 2021;10(5):1105.","journal-title":"J Clin Med"},{"issue":"6","key":"440_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"1","key":"440_CR25","first-page":"37","volume":"25","author":"Y Kubo","year":"2008","unstructured":"Kubo Y, Kazui H, Yoshida T, Kito Y, Kimura N, Tokunaga H, et al. Validation of grading scale for evaluating symptoms of idiopathic normal-pressure hydrocephalus. DEM. 2008;25(1):37\u201345.","journal-title":"DEM"},{"issue":"13","key":"440_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12987-016-0044-z","volume":"22","author":"M Ishikawa","year":"2016","unstructured":"Ishikawa M, Yamada S, Yamamoto K. Early and delayed assessments of quantitative gait measures to improve the tap test as a predictor of shunt effectiveness in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS. 2016;22(13):20.","journal-title":"Fluids Barriers CNS"},{"issue":"9","key":"440_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","volume":"39","author":"JC Morris","year":"1989","unstructured":"Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part I. clinical and neuropsychological assessment of Alzheimer\u2019s disease. Neurology. 1989;39(9):1159\u201365.","journal-title":"Neurology"},{"issue":"3","key":"440_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3233\/JAD-201363","volume":"81","author":"O Nerg","year":"2021","unstructured":"Nerg O, Junkkari A, Hallikainen I, Rauramaa T, Luikku A, Hiltunen M, et al. The CERAD neuropsychological battery in patients with idiopathic normal pressure hydrocephalus compared with normal population and patients with mild Alzheimer\u2019s disease. J Alzheimers Dis. 2021;81(3):1117\u201330.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"440_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u2018Mini-mental state\u2019. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res."},{"issue":"1","key":"440_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1212\/01.wnl.0000167607.63000.38","volume":"65","author":"MJ Chandler","year":"2005","unstructured":"Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, et al. A total score for the CERAD neuropsychological battery. Neurology. 2005;65(1):102\u20136.","journal-title":"Neurology"},{"issue":"20","key":"440_CR31","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","volume":"78","author":"TT Sepp\u00e4l\u00e4","year":"2012","unstructured":"Sepp\u00e4l\u00e4 TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012;78(20):1568\u201375.","journal-title":"Neurology"},{"issue":"4","key":"440_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/jep.12158","volume":"20","author":"RW Bohannon","year":"2014","unstructured":"Bohannon RW, Glenney SS. Minimal clinically important difference for change in comfortable gait speed of adults with pathology: a systematic review. J Eval Clin Pract. 2014;20(4):295\u2013300.","journal-title":"J Eval Clin Pract"},{"key":"440_CR33","doi-asserted-by":"publisher","DOI":"10.3171\/2019.6.JNS19613","author":"K Kwan","year":"2019","unstructured":"Kwan K, Arapi O, Wagner KE, Schneider J, Sy HL, Ward MF, et al. Cerebrospinal fluid macrophage migration inhibitory factor: a potential predictor of cerebral vasospasm and clinical outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019. https:\/\/doi.org\/10.3171\/2019.6.JNS19613.","journal-title":"J Neurosurg"},{"issue":"3","key":"440_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/bja\/aet149","volume":"111","author":"ER Zanier","year":"2013","unstructured":"Zanier ER, Zoerle T, Fiorini M, Longhi L, Cracco L, Bersano A, et al. Heart-fatty acid-binding and tau proteins relate to brain injury severity and long-term outcome in subarachnoid haemorrhage patients. BJA British J Anaesth. 2013;111(3):424\u201332.","journal-title":"BJA British J Anaesth"},{"key":"440_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00376","author":"L Lagerstedt","year":"2020","unstructured":"Lagerstedt L, Azurmendi L, Tenovuo O, Katila AJ, Takala RSK, Blennow K, et al. Interleukin 10 and heart fatty acid-binding protein as early outcome predictors in patients with traumatic brain injury. Front Neurol. 2020. https:\/\/doi.org\/10.3389\/fneur.2020.00376.","journal-title":"Front Neurol"},{"issue":"2","key":"440_CR36","first-page":"152","volume":"3","author":"M Foote","year":"2012","unstructured":"Foote M, Zhou Y. 14-3-3 Proteins in neurological disorders. Int J Biochem Mol Biol. 2012;3(2):152\u201364.","journal-title":"Int J Biochem Mol Biol"},{"issue":"14","key":"440_CR37","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/jcm10143009","volume":"10","author":"M Dulewicz","year":"2021","unstructured":"Dulewicz M, Kulczy\u0144ska-Przybik A, S\u0142owik A, Borawska R, Mroczko B. Fatty acid binding protein 3 (FABP3) and apolipoprotein E4 (ApoE4) as lipid metabolism-related biomarkers of Alzheimer\u2019s disease. J Clin Med. 2021;10(14):3009.","journal-title":"J Clin Med"},{"issue":"11","key":"440_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/CIA.S105769","volume":"17","author":"M Giri","year":"2016","unstructured":"Giri M, Zhang M, L\u00fc Y. Genes associated with Alzheimer\u2019s disease: an overview and current status. Clin Interv Aging. 2016;17(11):665\u201381.","journal-title":"Clin Interv Aging"},{"issue":"24","key":"440_CR39","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1242\/jcs.037457","volume":"122","author":"BV Desai","year":"2009","unstructured":"Desai BV, Harmon RM, Green KJ. Desmosomes at a glance. J Cell Sci. 2009;122(24):4401\u20137.","journal-title":"J Cell Sci"},{"issue":"1","key":"440_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12987-022-00346-8","volume":"19","author":"SK Halder","year":"2022","unstructured":"Halder SK, Sapkota A, Milner R. The impact of genetic manipulation of laminin and integrins at the blood\u2013brain barrier. Fluids Barriers CNS. 2022;19(1):50.","journal-title":"Fluids Barriers CNS"},{"issue":"84","key":"440_CR41","doi-asserted-by":"publisher","first-page":"110028","DOI":"10.1016\/j.cellsig.2021.110028","volume":"1","author":"A Corona","year":"2021","unstructured":"Corona A, Blobe GC. The role of the extracellular matrix protein TGFBI in cancer. Cell Signal. 2021;1(84):110028.","journal-title":"Cell Signal"},{"key":"440_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2014.00006","author":"RRH Anholt","year":"2014","unstructured":"Anholt RRH. Olfactomedin proteins: central players in development and disease. Front Cell Dev Biol. 2014. https:\/\/doi.org\/10.3389\/fcell.2014.00006.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"440_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12035-009-8076-x","volume":"40","author":"SI Tomarev","year":"2009","unstructured":"Tomarev SI, Nakaya N. Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology. Mol Neurobiol. 2009;40(2):122\u201338.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"440_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0378-1119(02)00840-5","volume":"296","author":"K Imiya","year":"2002","unstructured":"Imiya K, Ishizaki T, Seiki T, Saito F, Inazawa J, Oka S, et al. cDNA cloning, genomic structure and chromosomal mapping of the mouse glucuronyltransferase-S involved in the biosynthesis of the HNK-1 carbohydrate epitope. Gene. 2002;296(1):29\u201336.","journal-title":"Gene"},{"issue":"1","key":"440_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2045-8118-9-23","volume":"9","author":"AC Luissint","year":"2012","unstructured":"Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012;9(1):23.","journal-title":"Fluids Barriers CNS"},{"key":"440_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.689098","author":"T Lv","year":"2021","unstructured":"Lv T, Zhao B, Hu Q, Zhang X. The glymphatic system: a novel therapeutic target for stroke treatment. Front Aging Neurosci. 2021. https:\/\/doi.org\/10.3389\/fnagi.2021.689098.","journal-title":"Front Aging Neurosci"},{"key":"440_CR47","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/bs.irn.2020.02.006","volume":"154","author":"M Braun","year":"2020","unstructured":"Braun M, Iliff JJ. The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases. Int Rev Neurobiol. 2020;154:413\u201336.","journal-title":"Int Rev Neurobiol"},{"issue":"82","key":"440_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2020.11.009","volume":"1","author":"YJ Bae","year":"2021","unstructured":"Bae YJ, Choi BS, Kim JM, Choi JH, Cho SJ, Kim JH. Altered glymphatic system in idiopathic normal pressure hydrocephalus. Parkinsonism Relat Disord. 2021;1(82):56\u201360.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"440_CR49","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/nan.12420","volume":"44","author":"PK Eide","year":"2018","unstructured":"Eide PK, Hansson HA. Astrogliosis and impaired aquaporin-4 and dystrophin systems in idiopathic normal pressure hydrocephalus. Neuropathol Appl Neurobiol. 2018;44(5):474\u201390.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"440_CR50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1085\/jgp.200308803","volume":"121","author":"WG Hill","year":"2003","unstructured":"Hill WG, Kaetzel MA, Kishore BK, Dedman JR, Zeidel ML. Annexin A4 reduces water and proton permeability of model membranes but does not alter aquaporin 2\u2013mediated water transport in isolated endosomes. J Gen Physiol. 2003;121(5):413\u201325.","journal-title":"J Gen Physiol"},{"issue":"3","key":"440_CR51","doi-asserted-by":"publisher","first-page":"e91974","DOI":"10.1371\/journal.pone.0091974","volume":"9","author":"OT Pyykk\u00f6","year":"2014","unstructured":"Pyykk\u00f6 OT, Lumela M, Rummukainen J, Nerg O, Sepp\u00e4l\u00e4 TT, Herukka SK, et al. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. PLoS ONE. 2014;9(3):e91974.","journal-title":"PLoS ONE"},{"key":"440_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ensci.2017.04.002","volume":"7","author":"J Andersson","year":"2017","unstructured":"Andersson J, Rosell M, Kockum K, S\u00f6derstr\u00f6m L, Laurell K. Challenges in diagnosing normal pressure hydrocephalus evaluation of the diagnostic guidelines. eNeurologicalSci. 2017;7:27\u201331.","journal-title":"eNeurologicalSci"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-023-00440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-023-00440-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-023-00440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:06:06Z","timestamp":1685973966000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-023-00440-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1186\/s12987-023-00440-5","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki and all patients provided informed consent. The Research Ethics Committee of the Northern Savo Hospital District (decision No 276\/13.02.00\/2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors report no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}